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Abstract
Background: Breast cancer is a disease characterised by both genetic and epigenetic alterations. Epigenetic
silencing of tumour suppressor genes is an early event in breast carcinogenesis and reversion of gene silencing by
epigenetic reprogramming can provide clues to the mechanisms responsible for tumour initiation and progression.
In this study we apply the reprogramming capacity of oocytes to cancer cells in order to study breast oncogenesis.
Results: We show that breast cancer cells can be directly reprogrammed by amphibian oocyte extracts. The
reprogramming effect, after six hours of treatment, in the absence of DNA replication, includes DNA demethylation
and removal of repressive histone marks at the promoters of tumour suppressor genes; also, expression of the
silenced genes is re-activated in response to treatment. This activity is specific to oocytes as it is not elicited by
extracts from ovulated eggs, and is present at very limited levels in extracts from mouse embryonic stem cells.
Epigenetic reprogramming in oocyte extracts results in reduction of cancer cell growth under anchorage
independent conditions and a reduction in tumour growth in mouse xenografts.
Conclusions: This study presents a new method to investigate tumour reversion by epigenetic reprogramming.
After testing extracts from different sources, we found that axolotl oocyte extracts possess superior reprogramming
ability, which reverses epigenetic silencing of tumour suppressor genes and tumorigenicity of breast cancer cells in
a mouse xenograft model. Therefore this system can be extremely valuable for dissecting the mechanisms involved
in tumour suppressor gene silencing and identifying molecular activities capable of arresting tumour growth. These
applications can ultimately shed light on the contribution of epigenetic alterations in breast cancer and advance
the development of epigenetic therapies.
Background
Tissue homeostasis depends on tightly regulated
mechanisms controlling cell proliferation and differen-
tiation. Expression of proto-oncogenes and tumour sup-
pressor genes controls normal cell function, and
misregulation of these genes by both genetic and epige-
netic alterations is at the origin of cancer [1,2]. Genetic
changes include deletion, mutation and amplification of
genes, whereas epigenetic alterations occur without
change in DNA sequence via modification of chromatin
organisation, including DNA methylation, histone modi-
fications and expression of non-coding RNAs. The role
of epigenetic alterations in tumourigenesis has been
recognised in different types of malignancies, including
breast cancer [1].
In the breast, abnormal epigenetic regulation of genes
regulating the cell cycle, apoptosis, DNA repair, cell
adhesion and signalling leads to tumour formation, its
progression, and drug resistance [3]. Epigenetic altera-
tions prevail over genetic abnormalities in initial stages
of breast tumour development. For instance, silencing of
CDKN2A (p16INK4A), HOXA and PCDH gene clusters
by DNA methylation together with over-expression of
Polycomb proteins BMI-1, EZH2 and SUZ12 occurs
during spontaneous or induced transformation of
human mammary epithelial cells [4,5]. Methylation of
several homeobox genes is also observed in ductal carci-
noma in situ and stage I breast tumours [6].
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the chromatin are reversible and therefore are suitable
targets for reversal or attenuation of malignancy. The
question of how tumours can be reprogrammed is intri-
guing, and determining how a cancer cell can be repro-
grammed back to a normal cell phenotype is important
not only for understanding the molecular pathways of
the disease but also for diagnostic and therapeutic inter-
vention [7].
Embryonic environments that program cell fate during
development are able to reverse tumorigenicity [8].
Landmark experiments have shown that teratocarci-
noma cells are reprogrammed when injected into a
mouse blastocyst resulting in normal tissue derived
from tumour cells in chimeric mice [9]. Tumorigenicity
of metastatic melanoma cells is also reduced when cells
are injected into zebrafish [10], chicken [11] and mouse
embryos [12] or when they are cultured on 3D-matrices
conditioned with human embryonic stem cells [13].
Nuclear transfer (NT) experiments have demonstrated
that oocytes can fully reset the epigenotype of somatic
cells [14] and this ability has been exploited to re-
establish developmental potential in teratocarcinoma,
medulloblastoma and melanoma cells to extents that
depend on the degree of non-reprogrammable karyoty-
pic abnormalities of the donor tumour cell nucleus
[15-17]. Because NT experiments depend on the ability
of reprogrammed cells to support embryonic develop-
ment, with either formation of viable offspring or blasto-
cyst-derived embryonic stem cells as potential outcomes,
they are not easily amenable to dissecting the molecular
mechanisms involved in tumour reversion. Understand-
ably, NT experiments also do not allow the study of
human tumour cells.
An alternative method to reprogram cells is using
oocyte extracts as an ex-ovo system [18]. Extracts made
from amphibian oocytes are of particular interest, since
they are available in large quantities and they possess
reprogramming abilities similar to those of mammalian
oocytes [19-22]. We have previously shown that amphi-
bian oocyte extracts possess activities able to modify
DNA methylation and histone marks, together contri-
buting to the remodelling of somatic cell chromatin
[21,23]. In addition, we have introduced oocytes from
axolotls, a urodele (salamander) amphibian, as a source
of reprogramming extract based on our previous
demonstrations that urodeles are genetically more simi-
lar to mammals and the molecular mechanisms govern-
ing the early development of urodeles and mammals are
conserved [24-28]. In this study we analyse the relative
efficiencies of extracts from oocytes of axolotl and Xeno-
pus for their ability to reverse epigenetic alterations
within breast cancer cell chromatin. Our results show
that axolotl oocyte extracts reprogram cancer cell
chromatin with high efficiency, reversing epigenetic
silencing and activating expression from tumour sup-
pressor genes whose repression is involved in breast
tumorigenesis. In addition, we show long term suppres-
sion of tumour growth in vivo by reprogramming with
oocyte molecules.
Results and Discussion
Oocyte extracts induce expression of silenced tumour
suppressor genes
Understanding the molecular mechanisms involved in loss
of tumour suppressor gene function represents a major
hurdle for cancer therapies, towards which reversion of
cancer cell tumorigenicity can provide important clues. In
this study we asked whether epigenetically silenced
tumour suppressor genes could be reprogrammed to a
transcriptionally active state by the chromatin remodelling
activities present in oocyte extracts. A panel of genes
known to be silenced in breast cancers were selected to
address this question. These genes were either not
expressed or were expressed at very low levels in MCF-7
and HCC1954 cell lines, representing luminal and basal
breast cancer phenotypes, respectively (Table 1).
We have previously shown that oocytes of two amphi-
bian species (Xenopus laevis and Ambystoma mexica-
num or axolotl) are able to induce chromatin
remodelling in somatic cells [21,23], and therefore we
tested whether extracts made from prophase oocytes
could alter epigenetic marks of cancer cells. Digitonin
treatment of breast cancer cells gently permeabilises cel-
lular and nuclear membranes, as demonstrated by their
cytosolic permeability to 70KDa FITC-dextran and their
viability after extract treatment (Additional file 1: Figure
S1). Our previous work shows that chromatin remodel-
ling occurs within 3 to 6 hours when fibroblasts are
incubated in oocyte extracts [21,23], so we chose the
longest time point to assess reprogramming of tumour
Table 1 Expression of tumour suppressor genes in
reprogrammed breast cancer cells
Gene MCF-
7
MCF-7 in
AOE
HCC1954 HCC1954 in
AOE
HMEC
RARB - + - ++ +
CST6 - + - ++
CCND2 - + - + +++
GAS2 - + - + +++
ST18 -- - - +
SRBC -- - - +
SCGB3A1 -- - - +
RASSF1A -- - - +
GSTP1 -- - - +
CDKN2A -* n/a - ++
* = deleted in MCF-7; n/a = not applicable.
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Page 2 of 14suppressor genes. Both axolotl and Xenopus oocyte
extracts (AOE and XOE, respectively) were able to
induce re-expression of RARB, CST6, CCND2, GAS2
and CDKN2A genes. Importantly, re-expression of
RARB, CST6, CCND2 was observed in both breast can-
cer cell lines (CDKN2A expression was only investigated
in HCC1954 cells since this gene is deleted in MCF-7)
(Figure 1). The reprogramming activity of AOE was
greater than XOE for all genes with the exception of
CDKN2A, which is induced to the same extent by either
extract. The relative level of induced gene expression
varied between the two cell lines; however, not all the
reprogrammed tumour suppressor genes were re-
expressed at levels similar to those of normal human
mammary epithelial cells (HMEC). Also, some of the
genes analysed (ST18, SRBC, SCGB3A1, RASSF1A,
GSTP1)d i dn o ta l t e rt h e i re x p ression in response to
extract treatment (Table 1). The fact that only a sub-set
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Figure 1 Expression of tumour suppressor genes after reprogramming in oocyte, egg and embryonic stem cell extracts Expression of
RARB, CST6, CCND2, GAS2 and CDKN2A after 6 hours reprogramming analysed by Q-PCR. Data are shown as fold increase compared to the
calibrator sample (UN: untreated cells). Relative quantification to the expression of ACTIN (ACTB) was performed for each gene. Study of CDKN2A
expression of was only performed in HCC1954 since this gene is deleted in MCF-7 cells.* indicates P < 0.05 for treated groups different from UN.
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after treatment suggests that some genes may be more
susceptible to reprogramming than others. Indeed, silen-
cing of cancer-related genes is mediated by epigenetic
modifications encompassing wide genomic regions [29],
so it is possible that reprogramming of some tumour
suppressor genes may depend on their genomic context.
Alternatively, factors required for transcriptional activa-
tion might not be present, and/or the time of incubation
may not have been sufficient to induce re-expression of
all silenced domains. Nevertheless, the data clearly
demonstrate that re-activation of tumour suppressor
genes is highly specific and restricted to activities con-
tained in prophase oocytes, as no effect was observed
when cells were treated with matured (Metaphase II)
Xenopus egg extracts (XEE) (Figure 1). Because eggs are
transcriptionally inert, these results suggest that tran-
scriptional activation is induced by factors present in
oocytes [21]. Further, oocyte extracts sustain binding of
TATA-binding protein to transcriptionally active pro-
moters [20], and we have previously demonstrated that
amphibian extracts restore Polymerase II transcription
in mammalian cells incubated at amphibian compatible
temperatures (17°C). These results suggest that during
the incubation period transcription is directed by
amphibian molecules [21].
We next compared the reprogramming capacity of these
extracts with extracts prepared from embryonic stem
cells (ESC), as it has been reported that ESC extracts
(ESCE) can also reprogram transcription of somatic cells
to pluripotency [20,23,30]. Mouse ESCE were used so
that we could control for activation of human genes in
this mammalian heterologous system; reprogramming
was performed at mammalian physiological temperature
(37°C). Surprisingly, ESCE only induced expression of
GAS2 (Figure 1). Epigenetic silencing of tumour sup-
pressor genes involves diverse mechanisms, including
DNA methylation, histone modifications and expression
of non coding RNAs [2]. It is therefore possible that
activities contained in oocyte and ESC extracts can
differentially reprogram these epigenetic marks. The
limited reprogramming capacity of ESCE that we demon-
strate here is in agreement with a previous report in
which changes in tumour suppressor gene expression
were not observed when teratocarcinoma cells were
used to reprogram somatic cells to pluripotency [31].
Taken together, our results highlight intrinsic differ-
ences in the reprogramming ability of oocytes and ESC
for tumour suppressor genes, which we believe extend
from the natural chromatin remodelling activities found
in oocytes [18].
Intriguingly, AOE was consistently more efficient in
re-activating the majority of silenced genes compared
with the activities in XOE. It is important in this regard
to note that axolotl oocytes were chosen for this study
for the specific reason that urodele amphibians reflect
the ancestral amphibian state from which mammals
evolved, and they are therefore more genetically similar
to mammals than are frogs [25-28]. As a consequence,
transcription factor compatibility with mammalian target
sequences would be expected to be greater, and axolotl
oocytes would more closely reflect the epigenetic remo-
delling activity of mammalian oocytes [25-28], (ADJ,
unpublished). Hence, AOE provides a powerful tool to
identify mechanisms that mediate the reversal of epige-
netic silencing of tumour suppressor genes involved in
human cancers.
Demethylation of tumour suppressor gene promoters by
oocyte extracts
Amphibian oocytes possess replication independent
DNA demethylating activity and they can reduce DNA
methylation at a genome-wide level as well as at pluri-
potency gene promoters in mammalian cells [22,23].
Because epigenetically silenced tumour suppressor genes
are generally hypermethylated in breast cancer, we next
sought to determine whether the re-activation of
silenced genes was due to a reduction of DNA methyla-
tion at promoter regions. Bisulphite sequencing shows
demethylation of tumour suppressor gene promoters
after exposure to AOE and XOE, when compared to
untreated control cells (P < 0.05, Figure 2). AOE
induced higher levels of demethylation for RARB and
CST6 promoters compared to XOE (P < 0.05), but
CDKN2A and CCND2 showed similar levels of
demethylation by either extract. This result correlates
with the greater efficiency of AOE in inducing gene
expression of RARB and CST6 compared to XOE,
whereas CDKN2A expression is induced to similar levels
by either extract. However, this does not explain the
greater induction of CCDN2 expression by AOE. Inter-
estingly, ESCE induced limited demethylation of RARB
and CDKN2A genes, which is consistent with the inabil-
ity of this extract to re-activate their expression. Recent
work indicates that active DNA demethylation in
oocytes is controlled by base excision repair [32], and
these mechanisms might be less active in ESC. Consis-
tent with gene expression results, we did not observe
DNA demethylation in the promoters for two of the
tumour suppressor genes that were not reprogrammed
by oocytes extracts, RASSF1A and ST18 (data not
shown). We do not interpret this result as a limited
activity of the oocyte extracts, but rather as a reflection
of the refractory nature of some silenced promoters to
demethylation under these experimental conditions.
Importantly, extract-induced demethylation at promo-
ter regions was not randomly distributed among CpG
dinucleotides. Demethylation of CGs number 8-13 was
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Page 4 of 14found for RARB, CGs 1-8, 14-18, 25 and 31 for CST6,
CGs 1-7 and 21-28 for CCND2,a n dC G s1 - 9a n d1 9 - 2 8
for CDKN2A. Interestingly, the majority of these
demethylated CpG residues contain putative Sp1 sites
(Table 2), suggesting that DNA methylation mediated by
oocyte and ESC extracts is driven specifically at these
genomic regions to reactivate transcription. Reprogram-
ming experiments with somatic cells in Xenopus oocytes
support these conclusions. For example, re-activation
and demethylation of the Oct-4 gene promoter, after
injection of thymocytes into Xenopus oocytes, is strictly
dependent on the presence of a Sp1 site in its promoter
[22]. Although it is well established that the transcription
ESCE
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Figure 2 DNA methylation analysis of tumour suppressor genes by bisulfite sequencing. Bisulfite sequencing of RARB, CST6, CCND2 (MCF-
7 cells), and CDKN2A (HCC1954 cells) gene promoters after 6 hours reprogramming. Schematics indicate the position of analysed CpG islands in
promoter regions. A minimum of 10 clones were analysed for each gene and average loss of methylation was calculated for each
reprogramming treatment. Black circles indicate metylated CGs, white circles indicate unmethylated CGs. Reprogramming in AOE produced the
highest levels of demethylation (P < 0.05; a = AOE, XOE, ESCE vs UN; b = AOE vs XOE; c = AOE vs ESCE).
Table 2 Sp1 sites in demethylated tumour suppressor
gene promoters
RARB CST6 CCND2 CDKN2A
Number of
demethylated CGs
8-13 1-8, 14-18,
25, 31
1-7, 21-28 1-9,
19-28
Number of
demethylated CGs
containing Sp1 sites
12 5, 12, 13 1, 2 9, 10, 22
Putative transcription
factors binding sites
contained in
demethylated CGs
NF-
kappaB,
c-Re1
GATA-1,
Ahr/Arnt
CREB, MYC,
USF1, MAX,
SRY, MZF-1
USF1,
MZF-1,
CP2
Putative transcription factor binding sites as determined by TFSEARCH http://
www.cbrc.jp/research/db/TFSEARCH.html.
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from CpG island methylation [33,34], it is remarkable
that this site can be targeted specifically for demethyla-
tion in the promoters of tumour suppressor genes, with
high efficiency, by DNA demethylating complexes pre-
sent in the extracts. It will now be interesting to identify
how targeted demethylation is regulated.
Previous work demonstrates that amphibian oocytes
induce expression of pluripotency genes in somatic cells
[22,23]. As re-expression of these genes in cancer cells
may induce an adverse cancer stem cell phenotype, we
investigated whether AOE can induce demethylation of
OCT-4 and NANOG gene promoters, as well as expres-
sion of the respective proteins. After 6 hours of repro-
gramming and 6 days of culture, we observed no change
in DNA methylation at pluripotency gene promoters
(Additional file 2: Figure S2A). Consistently, OCT-4 was
not expressed after 6 days; however we detected
NANOG protein expression in untreated and treated
cells, likely as result of cross-reactivity of the NANOG
antibody with the protein encoded by the NANOGP8
pseudogene (Additional file 2: Figure S2B). Cancer cells
predominantly express NANOG transcripts derived from
the NANOGP8 retrogene and because the protein
encoded by the pseudogene is almost identical to the
native NANOG protein, it can be easily recognised by
anti-NANOG antibodies [35].
Remodelling of histone marks by oocyte extracts
We next investigated the remodelling of histone marks
at re-activated gene promoters, in order to establish the
relationship between this epigenetic modification and
DNA demethylation in breast cancer. We focussed our
attention on the RARB, CDKN2A and GAS2 promoters
(Figure 3). Chromatin immunoprecipitation (ChIP) shows
that AOE and XOE reduce transcription-repressive his-
tone marks, such as trimethylation of histone H3 at
lysine 27 (H3K27me3), trimethylation of histone H3
at lysine 9 (H3K9me3), and dimethylation of histone
H3 at lysine 9 (H3K9me2). Trimethylated lysine 4 at his-
tone H3 (H3K4me3), representing a transcription-active
mark, was modified at RARB and GAS2 promoters, but
n o ta tt h eCDKN2A promoter. H3K4me3 was found in
each of the promoters we analysed, suggesting that silen-
cing results from the addition of repressive epigenetic
marks. Interestingly, we observed a modest increase in
acetylation of Histone H3 lysine 9 (H3K9ac), which may
relate with the low levels of transcriptional activation
obtained for some genes. Of all genes analysed, GAS2
w a st h eo n l yo n et ob er e - a c t i v a t e db yE S C E .B e c a u s e
GAS2 expression is not regulated by DNA methylation
[36], we analysed the effect of ESCE on remodelling of
histone marks in its promoter region. ESCE effectively
reduced H3K9me3, H3K9me2 and H3K27me3 marks,
supporting the observed gene activation (Additional file
3: Figure S3).
Taken together, our results show very effective epige-
netic reprogramming of tumour suppressor gene pro-
moters by oocyte extracts, encompassing DNA
demethylation and reversion of histone marks to a more
euchromatic state. By comparison, treatment with 5-
aza-2’-deoxycytidine can demethylate DNA in the
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Figure 3 Reprogramming of histone marks by oocyte extracts.
Analysis of RARB, CDKN2A and GAS2 gene promoters by ChIP. Data
are presented as fold enrichment to input chromatin and indicate
reprogramming of histone repressive (H3K9me3, H3K9me2,
H3K27me3) and active (H3K4me3, H3K9Ac) marks by different
extracts after 6 hours of treatment. * indicates P < 0.05 for treated
groups different from UN.
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Page 6 of 14promoters of tumour suppressor genes, but H3K9me3
and H3K27me3, which characteristically mark hetero-
chromatin, are often retained [37]. Most importantly,
oocyte extracts induce expression from repressed
tumour suppressor genes, and the higher level of expres-
sion induced by AOE than XOE correlates with a more
robust targeting of demethylating activity in these
extracts. Clearly, identifying the molecules that partici-
pate in the reprogramming of tumour suppressor gene
expression could provide a route to the development of
therapeutic strategies for the treatment of breast cancer.
Stability of tumour suppressor gene reprogramming
Because epigenetic reprogramming occurs within
6 hours of incubation in AOE, and in the absence of
DNA replication, we sought to determine whether the
epigenetic remodelling was stable. We specifically asked
if the RARB gene remained active and responsive to reti-
noic acid (RA) treatment. We created transgenic cell
lines carrying a RARB promoter fused to Firefly lucifer-
ase (RARB-Lux) to follow reprogramming over time.
Silencing of the exogenous RARB promoter in MCF-7
and HCC1954 cell lines occurred rapidly, similar to pre-
vious studies [36]; and treatment with RA activated the
reporter in responsive MCF-7 cells, but not HCC1954
cells (Figure 4A). In response to treatment with AOE,
activity from the transfected RARB promoter was
re-established in HCC1954 cells, and was maintained
for at least 6 days (~5 population doublings) in culture
(Figure 4B). In addition, expression from this promoter
remained responsive to RA stimulation, indicating that
stable reprogramming induced by AOE was maintained
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Figure 4 Epigenetic reprogramming stability of tumour suppressor genes in AOE. Reprogramming of the tumour suppressor gene RARB
persists 6 days after treatment of MCF-7 and HC1954 cells with AOE. (A) Promoter activity in HMEC, MCF-7 and HCC1954 cells with or without
RA treatment measured by luciferase assay (* indicates P < 0.05 for RA treated cells different from the untreated group). (B) RARB promoter in
retinoic acid resistant HCC1954 cells can respond to RA after reprogramming (P < 0.05; a = AOE and AOE+RA vs UN; b = AOE + RA vs AOE). (C)
RARB expression by Q-PCR. * indicates P < 0.05 of treated cells compared to UN. (D) DNA demethylation is maintained in HCC1954 cells after 6
days of treatment as shown by bisulfite sequencing (similar results were obtained with MCF-7 cells).
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Page 7 of 14for the duration of the culture period. We confirmed this
by showing that induced expression of the endogenous
RARB gene was also maintained (Figure 4C), though the
relative level of expression diminished over time. We
then investigated the stability of demethylated CG resi-
dues by bisulphite sequencing. Consistent with the
expression data, the results of these experiments show
that the transcriptionally competent demethylated state
of the RARB promoter was maintained, even though the
cells had undergone several rounds of DNA replication
(Figure 4D). Previous work indicates that the pluripo-
tency gene Oct-4 undergoes gradual reprogramming
after exposure to amphibian oocyte or egg molecules
over 3-5 days, suggesting that replication-dependent
reprogramming is necessary to reactivate some silenced
genes [22,23,38]. However, this is not the case for RARB;
furthermore those tumour suppressor genes that were
not re-activated after 6 hours of AOE treatment, such as
RASSF1A and ST18, remained silenced in long term
culture (data not shown). Our results suggest that the
maintenance of demethylated cytosine residues through
the replication process is essential to long term repro-
gramming, which includes the responsiveness to induc-
tive signals, such as RA. We view understanding how
responsiveness to differentiation signals can be repro-
grammed into the cancer cell genome as an important
challenge with significant implications for therapeutic
interventions.
Reprogramming of tumour suppressor genes and reversal
of malignant phenotype
In this study we show that RARB, CST6, CCND2, GAS2
and CDKN2A tumour suppressor genes are repro-
grammed by oocyte extracts. Because these genes con-
trol cell growth, death and invasion, we next studied the
effect of reversing the silenced expression state on the
malignancy of breast cancer cells. Again, AOE was used
because of its superior reprogramming activity. Figure
5A shows no difference in cell numbers when cancer
cells were maintained in culture for 1, 3, or 6 days after
reprogramming by AOE, indicating that extract treat-
ment is non-toxic, and does not affect cell proliferation
after permeabilisation. We could not detect any differ-
ence in the distribution of cells through G1, S, or G2/M
phases of the cell cycle, nor in the percentage of apopto-
tic cells, when analysis was done at the same time points
(Additional file 4: Figure S4). We next tested whether
reprogramming affected the ability of transformed
MCF-7 cells to grow in anchorage-independent condi-
tions by performing soft agar assay. After 2 weeks of
growth in agar, control or treated cells formed colonies
that were counted under a stereomicroscope. A signifi-
cant reduction of colony size and number was observed
for cells treated with AOE (Figure 5B). The same effect
was not obtained when non-permeabilised cells were
exposed to AOE (Additional file 4: Figure S5). Reduction
of cancer cell proliferation, and induction of apoptosis,
has been reported in previous tumour reversion experi-
ments. For example, exposure to zebrafish embryo
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Figure 5 Effect of epigenetic reprogramming on malignant cell
phenotype. Cancer cell growth after reprogramming with AOE.
(A) Proliferation of MCF-7 cells after 1, 3 and 6 days of culture in
adherent conditions as measured by MTT assay. (B) Growth of MCF-
7 cells in anchorage-independent conditions. The top panels show
cultures stained with crystal violet and representative fields of view
of the same cultures in soft agar. The bottom panel show
quantification of colony number as counted under a
stereomicrosope. Bar = 100 μm. * indicates P < 0.05.
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Page 8 of 14extracts can reduce two dimensional growth of colon
cancer cells [39]. Similar effects have been reported for
breast cancer cells grown in soft agar after exposure to
Matrigel conditioned with human embryonic stem cells
[13], or in response to co-culture with human umbilical
cord matrix stem cells [40]. These effects are mediated
by extracellular factors, such as Nodal and cytokines;
however, we observed an effect of AOE on cancer cell
proliferation only after permeabilisation, suggesting that
reprogramming mediated by oocyte extract molecules is
not signalled through receptors on the cell surface, but
rather by the direct association of oocyte molecules with
the chromatin of cancer cells.
We next investigated the effect of AOE on cancer
cell growth in vivo after transplantation into immuno-
compromised mice. Tumours from reprogrammed cells
were significantly smaller than those from untreated
cells when analyzed after 8 weeks of transplantation
(Figure 6A). Histologically, both tumours appeared well
circumscribed but not encapsulated, with high degree of
nuclear pleomorphism. In addition, AOE-treated
tumours showed a significant decrease in the number of
mitotic divisions (Figure 6B: black arrows; Figure 6C).
The reduced tumour growth was associated with a
reduction of epithelial cells and an increase in interstitial
stroma (Figure 6C), which stained positive for collagen
(Figure 6D). These results show that the epigenetic
reprogramming induced by AOE induces stable changes
that result in long term suppression of tumorigenicity. It
will be now important to identify the oocyte-specific
molecules involved in this process, and the molecular
pathways responsible for the arrest of tumour growth.
In our view, the identification of these molecules will
provide a rich source of information for the design of
synthetic molecules that can be used for pharmaceutical
interventions.
Conclusions
This study describes a new method for investigating
reprogramming of silenced tumour suppressor genes
using oocyte extracts. Understanding the molecular
mechanisms of tumourigenesis has been central to
cancer research for decades and reports of tumour
reversion are creating exciting avenues to address this
important biological and biomedical question. Repro-
gramming in response to embryonic environments [8]
or by over-expression of embryonic factors [41,42] can
change cancer cell fate over many cell divisions. Repro-
gramming with oocyte molecules which does not require
DNA replication, can directly remodel cancer cell
chromatin and induce re-expression of silenced tumour
suppressor genes after only 6 hours of treatment. The
long-term effects of this treatment are reflected in
reduced tumour growth in vivo. This reprogramming
system can easily be adapted to understand how oocyte
chromatin remodelers and DNA demethylating com-
plexes are targeted to promoter regions of tumour sup-
pressor genes. Since oocyte-mediated demethylation
does not occur randomly, this system can be employed
to identify the mechanisms that maintain tumour sup-
pressor gene silencing in cancer cells. Although this
study focussed on reprogramming of selected tumour
suppressor genes, we show that AOE can induce stable
epigenetic reprogramming. Future studies will focus on
pure populations of reprogrammed cells, isolated by
selection in culture, to study their epigenotype at a gen-
ome-wide level. In this study we have used cancer cell
lines with complex genetic abnormalities. Since NT stu-
dies highlight that genetically abnormal cells are resis-
tant to tumour reversion [16], future studies will test
oocyte-mediated reprogramming on cells derived from
early stage tumours to elucidate the contribution of epi-
genetic alterations to the onset of breast oncogenesis.
Our data show that DNA methylation represents a
bottleneck to reprogramming since extracts of ESC can-
not efficiently reprogram hypermethylated tumour sup-
pressor genes. Defining the relationship between
different levels of epigenetic regulation for cancer-
related genes is essential for devising epigenetic thera-
pies and this system could be of paramount importance
for dissecting this aspect of the problem. Extracts of
axolotl oocytes show superior reprogramming capacity
and they present several practical advantages, including
cell size and availability. We propose that they can be a
valuable tool to understand how cells become malignant
and to advance the discovery of novel cancer therapies.
Methods
Cell culture and permeabilization
All culture reagents were from Invitrogen and chemicals
from Sigma unless otherwise indicated. Cells were incu-
bated in a 37°C humidified incubator with 5% C02.
M C F - 7a n dH C C 1 9 5 4c e l ll i n e sw e r ep u r c h a s e df r o m
ATCC and maintained in RPMI medium containing
10% fetal calf serum (FCS), 2 mM glutamine, 1% non-
essential amino acids, 1% sodium pyruvate, and 1% peni-
cillin/streptomycin. HMEC cells and HMEC complete
medium were from Invitrogen. HMEC were passaged by
incubation with 0.25% trypsin for 15 min at 37°C and
neutralisation with 0.1% soybean trypsin inhibitor.
CGR8 mouse ESC were obtained from ECACC and cul-
tured on gelatin-coated culture dishes in DMEM con-
taining 15% Hyclone stem cell screened FCS, 2 mM
glutamine, 1% non-essential amino acids, 1% sodium
pyruvate, 1% penicillin/streptomycin, 1000 U/ml of leu-
kemia inhibitory factor (Millipore) and 0.1 mM beta-
mercaptoethanol. NTERA2 cells (kindly donated by
Prof. Andrews, University of Sheffield) were cultured in
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Figure 6 Effect of epigenetic reprogramming on in vivo tumorigenicity. Macroscopic and microscopic analyses of tumour xenografts. (A)
Macroscopic appearance of untreated (UN) and AOE-treated tumour xenografts (AOE) and relative tumour growth curves (* indicates P < 0.05).
(B) Eosin-Haematoxylin staining of untreated tumour sections (black arrows: mitotic figures; Bar = 50 μm). (C) Number of mitotic figures for two
independent tumours in untreated (UN) and AOE-treated xenografts (AOE) (* indicates P < 0.05). (D) Interstitial stroma present in AOE-treated
tumours stained for collagen (blue staining; Bar = 50 μm).
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1% non-essential amino acids, and 1% penicillin/
streptomycin.
Cell permeabilisation was performed as previously
reported [21]. Briefly, cell suspensions (2 × 10
6 cells/ml)
were treated with 20 μg/ml digitonin in PB buffer
(170 mM potassium gluconate, 5 mM KCl, 2 mM
MgCl2,1m MK H 2PO4, 1 mM EGTA, 20 mM Hepes,
supplemented with 3 μg/ml leupeptin, 1 μg/ml aprotinin
and 1 μg/ml pepstatin A, pH 7.25, freshly prepared
prior to use) for 1-2 min on ice. Cells were washed in
cold PB buffer and permeabilisation was assessed by
staining with propidium iodide (PI) and 70 kDa FITC-
dextran.
Treatment of cells in oocyte, egg and ESC extracts
Axolotl and Xenopus oocyte/egg extracts (AOE, XOE
and XEE, respectively) were prepared from mature
females as described previously [21,23]. Mouse ESC
extracts (ESCE) were prepared according to Taranger
et al., [31].
Permeabilised cells were added to oocyte/egg and ESC
extracts (5,000 cells/μl extract) supplemented with an
energy regenerating system (150 μg/ml creatine phos-
phokinase, 60 mM phosphocreatine, 1 mM ATP) and
incubated at 17°C for AOE, 21°C for XOE and XEE, and
37°C for ESCE.
Gene expression analysis
Cells were collected and processed for RNA extraction
using Qiagen RNAeasy mini kit with Qiashredder and
DNAse treatment. cDNA synthesis was performed with
Superscript III reverse transcriptase (Invitrogen). Real
time PCR (Q-PCR) was performed using the 7500 Fast
Real-Time PCR System (Applied Biosystems). TaqMan
Gene expression master mix and TaqMan Gene expres-
sion assays were used (assay ID can be found in Addi-
tional file 5: Table S1). After validation of the
amplification efficiencies, the Relative Quantification
method (ΔΔCt) was used to quantify the gene expres-
sion levels of each gene relative to ACTB (ACTIN, endo-
genous control) for each sample. Results are represented
as fold increase in expression relative to untreated sam-
ple (UN) used as calibrator (mean ± sd, n = 3).
Western Blotting
Nuclear proteins were extracted with NucBuster™ Pro-
tein Extraction Kit (Calbiochem).
Extracted proteins were loaded into a 12% Acrylamide
gel (10 μg/lane), separated by SDS-PAGE electrophoresis
and blotted onto a PVDF membrane. Membranes were
blocked with 10% skimmed milk and then probed over-
n i g h ta t4 ° Cw i t har a b b i ta n t i - N A N O Ga n t i b o d y
(1:1,000, Peprotech) or goat anti-OCT-4 antibody
(1:1,000, Santa Cruz Biotechnology), in the presence of
0.05% Tween 20 and 5% milk. Peroxidase conjugated
donkey anti-rabbit (1:10,000; GE Healthcare) or anti-
goat (1:10,000; Sigma) antibodies were incubated for 1h
at RT. ECL plus kit (Amersham Biosciences) was used
to detect chemiluminescence.
Bisulfite genomic sequencing
G e n o m i cD N Aw a si s o l a t e du s i n gD N e a s yT i s s u ek i t
(Qiagen). Bisulfite genomic sequencing was carried out
as described previously [43]. Briefly, 1 μgo fg e n o m i c
DNA was used for bisulfite treatment (5 hours, 55°C)
and 1 μl of bisulfite converted DNA was used for PCR
reactions using 2.5 U of Platinum Taq polymerase
(Invitrogen) (primers are listed in Additional file 5:
Table S1). Primers spanning CpG island sequences were
designed using Methprimer software http://www.uro-
gene.org/methprimer/index1.html. Purified PCR pro-
ducts were either directly sequenced or cloned into
pGEM-T easy (Promega), with 10 or more clones of
each sample subjected to sequencing.
Chromatin Immunoprecipitation (ChIP)
ChIP experiments were performed using the Magna
ChIP A kit (Millipore). One million cells were used with
the following antibodies: ChIP grade rabbit polyclonal
anti-H3K27me3 (3 μg, Millipore 07-449), ChIP grade
rabbit polyclonal anti-H3K4me3 (3 μg, Abcam ab8580),
ChIP grade rabbit polyclonal anti-H3K9ac (1.5 μg,
Abcam ab4441), ChIP grade rabbit polyclonal anti-
H3K9me3 (2 μg, Abcam ab8898), ChIP grade mouse
monoclonal anti-H3K9me2 (2 μg, Abcam ab1220), IgG
from rabbit serum (4 μg, Sigma I5006). Immunoprecipi-
tated DNA was quantified by Q-PCR using the 7500
Fast Real-Time PCR System (Applied Biosystems) with
5 μl DNA (from a total of 50 μl). TaqMan Gene expres-
sion master mix and TaqMan Gene expression custom
assays (Applied Biosystem) were used (primers and
probes are listed in Additional file 5: Table S1). Data are
presented as “Fold enrichment” of precipitated DNA for
each histone modification relative to a 1/100 dilution of
input chromatin (mean ± sd, n = 3).
Luciferase assay
HMEC, MCF-7 and HC1954 cells were transfected with
Firefly RARB reporter and Renilla luciferase transfection
control pRL-TK (Promega) plasmids using Lipofecta-
mine 2000 (Invitrogen). The RARB reporter (containing
promoter sequence fragment -522 to +156) was
obtained by cloning into pGL3-Basic (Promega) at the
Nhe and Xho1 restriction sites in both orientations. The
vector with antisense promoter orientation was used as
control in transfection experiments. Retinoic acid (RA 1
μM, Sigma) treatment was performed for 24 hours.
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are presented as relative luciferase values to the negative
control (mean ± sd, n = 3).
Cell proliferation assay
Permeabilised MCF-7 cells were incubated in AOE and
after 6 hours plated at a density of 12.5 × 10
3 cells/cm
2
in triplicate. After 1, 3, and 6 days in culture MTT was
added at 5 mg/ml and incubated for 3 hours at 37°C.
The converted dye was dissolved by treatment with iso-
propanol containing 0.04N HCl and quantified by mea-
suring the absorbance at 570 nm with background
subtraction at 650 nm in a SmartSpec 3000 Spectro-
photometer (Bio-Rad Laboratories). Results are pre-
sented as mean ± sd, n = 3.
Apoptosis and cell cycle assays
MCF-7 cells treated in AOE were plated at a density of
5×1 0
3 cells/cm
2 in triplicate. After 1, 3, and 6 days in
culture cells were trypsinised and fixed with 70% ice-
cold ethanol for 30 min at -20°C. Cell were then centri-
fuged and stained in 50 μg/ml PI solution containing 0.1
mg/ml RNase A and 0.05% Triton X-100 for 30 min.
After washing, cells were resuspended in PBS and
50,000 cells analysed with a Beckman Coulter FC-500
flow cytometer.
Soft agar assay
MCF-7 cells (30,000/6 well) were seeded in 0.5 ml of
0.3% noble agar in complete RPMI medium overlaying a
1 ml 0.5% agar in the same medium. After 2 weeks cul-
ture cell colonies were stained with crystal violet and
colonies ≥ of 100 μmc o u n t e du n d e raM Z 1 2 5 Leica
stereomicroscope. For control experiments with non-per-
meabilised cells, cells were either incubated with AOE
for 6 hours and then plated in soft agar or cultured with
different amounts of AOE into the agar top layer. In the
latter case 10, 50 and 100 μl of AOE were added to the
top layer of soft agar together with MCF-7 cells (corre-
sponding to the same, 5-fold and 10-fold higher ratio of
cell/extract used with permeabilised cells).
Tumour xenografts
Female MF1 nude mice (Harlan-Olac) were anaesthe-
tised with Ketamine/Medetomidine and MCF-7 cells at
1.5 × 10
6 cells in a volume of 200 μlM a t r i g e lw e r e
injected sub-cutaneously into the left flank. In addition,
0.1 mg 17-beta-estradiol pellet (60-day release; Innova-
tive Research of America, US) implanted subcutaneously
into the scruff of each mouse. Tumour dimensions were
measured by calliper measurement of length and width
three times weekly and the volume calculated [(length
2
× width)/2] and clinical condition of the mice were
monitored by weekly body weight measurements for the
duration of the study (n = 4-6 for each time point). The
project was run under Home Office project PPL 40/
2962 which was awarded in November 2006 (Watson)
following local ethical approval. The study also adhered
to the UK Co-ordinating Committee for Cancer
Research (UKCCCR) guidelines. At termination,
tumours were excised, fixed in formalin and paraffin
embedded.
Histochemistry
Histology sections (5 μm) were stained with Eosin &
Haematoxylin and observed under a Leica DM5000B
microscope and Leica Application Suite software.
Mitotic figures were quantified by examination of 10
fields of view at high power magnification (630x) in two
independent tumours. Collagen was stained with the
Trichrome Stains (Masson, Sigma) according to manu-
facturer’s instructions.
Statistical analysis
GraphPad InStat3 software was used to perform statis-
tical analysis. Q-PCR and ChIP data were analysed by
one-way ANOVA with post Tukey’s multiple compari-
son test with a significance level set at P < 0.05. Bisul-
fite sequencing data were analysed by c
2 test with a
significance level set at P < 0.05. Cell proliferation, soft
agar assay and luciferase assay, data were analysed
with unpaired Student’s t-test (P < 0.05). Tumour
growth data were analysed by two-way ANOVA with
Bonferroni post-test (P < 0.05). Mitotic figures data
were analysed by one-way ANOVA with post Tukey’s
multiple comparison test with a significance level set
at P < 0.05.
Additional material
Additional file 1: Permeabilisation and viability of reprogrammed
cancer cells. The Figure S1 shows permeabilisation and viability of
MCF-7 cells after permeabilisation with digitonin and incubation in AOE.
(A) FITC-dextran (green) staining of the cytoplasm of permeabilised cells.
Note exclusion of dextran from the nucleus. (B) PI (red) staining of the
nucleus of permabilised cells. (C) Digitonin-treated cells show both
cellular and nuclear membrane permeability with preservation of
cytoplasm (merge). (D) Permeabilised cells treated with AOE for 6 hours
are viable and show presence of vacuoles due to treatment with
digitonin after 3 days in culture.
Additional file 2: Effect of AOE-mediated reprogramming on
expression of pluripotency genes. The Figure S2 shows methylation
of OCT-4 and NANOG promoters and relative protein expression after
reprogramming with AOE. (A) Methylation of OCT-4 and NANOG
promoters by direct sequencing after bisulfite conversion of DNA.
Schematics indicate the position of analysed CpG islands in promoter
regions. Black circles indicate metylated CGs, black/white circles indicate
partially methylated CGs. (B) Expression of OCT-4 and NANOG protein by
Western Blotting (10 μg protein/lane). NTERA2 cells were used as positive
control for expression of pluripotency genes. The Coomassie stained
SDS-PAGE gel is shown as loading control.
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Page 12 of 14Additional file 3: Reprogramming of GAS2 histone marks by ESCE.
Analysis of GAS2 gene promoter by ChIP. Data are presented as fold
enrichment to input chromatin and indicate reprogramming of histone
repressive (H3K9me3, H3K9me2, H3K27me3) and active (H3K4me3,
H3K9Ac) marks by ESCE after 6 hours of treatment. * indicates P < 0.05
for treated groups different from UN.
Additional file 4: Effect of reprogramming with AOE on cancer cell
growth. The data provided show the effect of epigenetic
reprogramming by AOE on MCF-7 cells. Figure S4: Cell cycle analysis
of reprogrammed cells. Cell cycle profiles of control and AOE-treated
cells analysed after 1, 3 and 6 days of treatment. Figure S5: Effect of
AOE on growth of non-permeabilised cells in soft agar.
Representative images of soft agar assay where different quantity of AOE
(10, 50 or 100 μl AOE: equivalent to the same, 5-fold and 10-fold the
quantity of extract per number of cells used in experiments with
permeabilisation) were included in the top agar layer with MCF-7 cells.
Equivalent results were obtained when non-permeabilised cells were
incubated with AOE for 6 hours and cultured in soft agar. Bar = 100 μm.
Additional file 5: Q-PCR assay ID, primers and probes. The Table S1
lists the TaqMan gene expression assays, primers and probes used in this
study.
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